DYNAMIC-III trial results: ctDNA blood test is a powerful tool to guide treatment choices for people with advanced colon cancer - report from ESMO 2025
Professor Jeanne Tie shares her thoughts on the DYNAMIC-III trial results were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:dynamic-iii-trial-results-ctdna-blood-test-powerful-tool-guide-treatment-choices-people-advanced-colon-cancer
--------
6:18
--------
6:18
Overcoming Therapeutic Challenges in High-risk Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Approach - report from ESMO 2025
Professor Dirk Schadendorf shares his thoughts on the overcoming therapeutic challenges in high-risk cutaneous squamous cell carcinoma at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:overcoming-therapeutic-challenges-high-risk-cutaneous-squamous-cell-carcinoma-multidisciplinary-approach
--------
7:09
--------
7:09
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials - report from ESMO 2025
Professor Christof Vulsteke shares her thoughts on the data from the phase 3 KEYNOTE-905 trial were presented at the ESMO Congress 2025. A treatment regimen consisting of neoadjuvant enfortumab vedotin-ejfv plus pembrolizumab, radical cystectomy plus pelvic lymph node dissection, and adjuvant EV plus pembrolizumab yielded significant improvements in multiple outcomes in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.Video: https://medicaldigest.org/scientific-contents/interview:keynote-905-paves-way-next-generation-mibc-trials
--------
4:14
--------
4:14
Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025
Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:durvalumab-combination-bcg-bcg-naive-high-risk-nmibc-final-analysis-phase-3-open-label-randomized-potomac-trial
--------
3:35
--------
3:35
Treatment Landscape in Resectable LA HNSCC - report from ESMO 2025
Professor Hisham M. Mehanna shares his thoughts on the treatment landscape in resectable LA HNSCC at ESMO 2005 at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:treatment-landscape-resectable-la-hnscc
The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.
Brasil